Truist analyst Jailendra Singh lowered the firm’s price target on Doximity to $28 from $33 and keeps a Hold rating on the shares after its Q1 results and guidance. The company cut its FY24 revenue and EBITDA outlook due to materially underperforming midyear upsells, lower expectations on new business, and lower renewal volume expansion, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DOCS:
- Doximity (NYSE: DOCS) Crashes after Lowered Guidance
- Doximity downgraded at Guggenheim after ‘another disappointing’ outlook
- Doximity downgraded to Hold at Needham on mixed Q1 results
- Doximity price target lowered to $24 from $28 at BofA
- Doximity price target lowered to $27 from $36 at Piper Sandler